2020肿瘤疫苗重磅盘点——肺癌、妇科肿瘤篇
<img src="https://mmbiz.qpic.cn/mmbiz_gif/oZVJebibh9RmLqYBt9InvOwP0iaXKG7ick0k64WYib00c1sOO7Ln4KGHKicrWCBxzAh4EOj8Ut0mlu89ib2Xu5riaoK3Q/640?wx_fmt=gif&tp=webp&wxfrom=5&wx_lazy=1" style="width: 50%; margin-bottom: 20px;"><p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">一年一度的元旦+圣诞“双旦”季即将来袭！但感受节日氛围的<span style="color: black;">同期</span>，<span style="color: black;">博主</span>刷着<span style="color: black;">资讯</span>，看到<span style="color: black;">持续</span>弹出的<span style="color: black;">近期</span>各大地区爆发的新增新冠病例，不禁感叹又到了新冠肺炎病情的爆发期。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">而面对疫情，疫苗可能是这场<span style="color: black;">劫难</span>的终极武器。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">那样</span>当肿瘤细胞遇到疫苗……又会碰撞出<span style="color: black;">怎么样</span>的火花呢？</strong></span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">针对</span>新冠病毒，其实已有<span style="color: black;">非常多</span>家药企宣布其疫苗研制大获成功。新冠病毒毕竟是<span style="color: black;">源自</span>于自然界，是和正<span style="color: black;">一般人</span>体细胞完全不同的病原体。人体的免疫系统对这类入侵的外敌，识别和处理起来本身就有<span style="color: black;">优良</span>，<span style="color: black;">因此呢</span>新冠疫苗的研制相对容易成功。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">而肿瘤细胞，则有<span style="color: black;">基本</span>的不同！</span>癌细胞<span style="color: black;">是由于</span>正常细胞“叛变”而来，本来是“自己人”，<span style="color: black;">然则</span>禁不起糖衣炮弹的<span style="color: black;">引诱</span>从而产生“叛变”，脱离正轨。这类“叛变”细胞<span style="color: black;">自动</span>设定增殖速度，当累积到数十亿个以上<span style="color: black;">咱们</span>才会有所察觉，<span style="color: black;">因此呢</span>要将其识别并一网打尽，非常困难。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/oZVJebibh9RmLqYBt9InvOwP0iaXKG7ick0MKc3wcL9K6cgEqXnULMpsKnqAaBPyf5rmHCmSALkw0iaFCpkoia2Lmog/640?wx_fmt=png&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">然则</span>，近年，<span style="color: black;">科研</span>者们<span style="color: black;">亦</span><span style="color: black;">逐步</span><span style="color: black;">发掘</span>了癌细胞的软肋。</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">癌细胞身上有特定的蛋白质，由致癌基因制造产生。肿瘤疫苗<span style="color: black;">能够</span><span style="color: black;">经过</span>改造过的基因或新抗原来<span style="color: black;">加强</span>更强的免疫反应，识别癌细胞上的特定的蛋白质，以此阻止癌细胞生长，<span style="color: black;">同期</span><span style="color: black;">亦</span>不<span style="color: black;">损伤</span>人体正常细胞。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">今天<span style="color: black;">博主</span>就来盘点一下发病率最高的两大癌种——<strong style="color: blue;">肺癌和妇科肿瘤</strong>，今年都有<span style="color: black;">那些</span><span style="color: black;">关联</span>疫苗<span style="color: black;">拥有</span>突破性<span style="color: black;">发展</span>：</p><img src="https://mmbiz.qpic.cn/mmbiz_svg/oLU121BePGns866fNeNCBA0E8n3Yic0oUCickfdZ9ZvdarMe37IJ1bsJ3nHO6fA1R9M3JNHXajhyarEJu3WYxib0PP9OSPeibRdR/640?wx_fmt=svg&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;">
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">肺癌</strong></p><img src="https://mmbiz.qpic.cn/mmbiz_svg/oLU121BePGns866fNeNCBA0E8n3Yic0oUCy1cqCFLLgv9PicxTG86bSyIaOHib4oHsDnE6Jic2bfvHfxQ24ibUMnMibZBtShDdftcF/640?wx_fmt=svg&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;">
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">01</strong></p><img src="https://mmbiz.qpic.cn/mmbiz_svg/oLU121BePGns866fNeNCBA0E8n3Yic0oUCickfdZ9ZvdarMe37IJ1bsJ3nHO6fA1R9M3JNHXajhyarEJu3WYxib0PP9OSPeibRdR/640?wx_fmt=svg&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;">
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">新型肺癌疫苗TedopiⅢ期<span style="color: black;">实验</span>数据<span style="color: black;">颁布</span>，竟能破解PD-1耐药！</strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2020年4月1日，OSE Immunotherapeutics<span style="color: black;">机构</span>宣布其新型抗癌疫苗Tedopi在非小细胞肺癌的Ⅲ期临床<span style="color: black;">实验</span>（代号为Atalante 1）取得了阳性结果，入组的所有<span style="color: black;">病人</span><span style="color: black;">在免疫<span style="color: black;">检测</span>点<span style="color: black;">控制</span>剂（PD-1）耐药或失败后</span>，二线或三线<span style="color: black;">运用</span>Tedopi疫苗，<span style="color: black;">一年的总<span style="color: black;">存活</span>率达到46%</span>，远超预设的25%！</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/oZVJebibh9RmLqYBt9InvOwP0iaXKG7ick0AM25JBLMM10lapcqibql8CHbFXD2T21QTicEusV4VhDJAjm4VkdrJWEQ/640?wx_fmt=png&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">一位54岁的晚期肺癌<span style="color: black;">病人</span>在经过5次的新型肺癌疫苗注射后，肿瘤就<span style="color: black;">快速</span>萎缩（从39毫米降至23毫米），截止<span style="color: black;">报告</span>时，<span style="color: black;"><span style="color: black;">存活</span>期<span style="color: black;">已然</span>超过20.6个月，<span style="color: black;">日前</span>仍在随访中</span>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/oZVJebibh9RmLqYBt9InvOwP0iaXKG7ick0ZGr1vT0h0cmBNNLuZX1piasmTrbreXtMJVng2TvIrY3DLfw6ALiaiaLWw/640?wx_fmt=png&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">02</strong></p><img src="https://mmbiz.qpic.cn/mmbiz_svg/oLU121BePGns866fNeNCBA0E8n3Yic0oUCickfdZ9ZvdarMe37IJ1bsJ3nHO6fA1R9M3JNHXajhyarEJu3WYxib0PP9OSPeibRdR/640?wx_fmt=svg&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;">
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">古巴EGF疫苗联合O药，延长<span style="color: black;">存活</span>期至13.7个月</strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">古巴EGF疫苗（CIMAvax-EGF）是一种比较古老的肺癌治疗性疫苗，2020ASCO会议<span style="color: black;">报告</span>了古巴EGF疫苗联合O药二线治疗NSCLC的I期<span style="color: black;">科研</span>结果。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">科研</span>共纳入13例<span style="color: black;">病人</span>，大部分<span style="color: black;">病人</span>PD-L1表达为0。结果<span style="color: black;">表示</span>，古巴EGF疫苗联合O药之后<span style="color: black;">病人</span><span style="color: black;">能够</span>更快达到足够的抗EGF效果，4剂古巴EGF疫苗联合O药后100％的<span style="color: black;">病人</span>抗EGF抗体滴度> 1：4000，而单独<span style="color: black;">运用</span>古巴EGF疫苗时的历史数据为56％。<span style="color: black;">这<span style="color: black;">寓意</span>着，即使PD-L1为阴性，疫苗联合免疫<span style="color: black;">检测</span>点<span style="color: black;">控制</span>剂<span style="color: black;">亦</span>能<span style="color: black;">生效</span>。</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/oZVJebibh9RmLqYBt9InvOwP0iaXKG7ick0DypjlqoODHERlEhia1lG8D5FlT8cT26XqBFu8zicfAynPsjGsSCSrE4g/640?wx_fmt=png&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">13例<span style="color: black;">病人</span>的<span style="color: black;">中位OS为13.7个月</span>，优于O药单药治疗PD-L1<10%<span style="color: black;">病人</span>的9.9个月；而完成4剂古巴EGF疫苗注射的10例<span style="color: black;">病人</span>中，<span style="color: black;">中位OS达到18.5个月</span>。说明<span style="color: black;">增多</span>古巴疫苗计量<span style="color: black;">能够</span>更好地<span style="color: black;">帮忙</span><span style="color: black;">病人</span>延长<span style="color: black;">存活</span>期。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">03</strong></p><img src="https://mmbiz.qpic.cn/mmbiz_svg/oLU121BePGns866fNeNCBA0E8n3Yic0oUCickfdZ9ZvdarMe37IJ1bsJ3nHO6fA1R9M3JNHXajhyarEJu3WYxib0PP9OSPeibRdR/640?wx_fmt=svg&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;">
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">NEO-PV-01疫苗+PD1，多癌种有效率可观！</strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">今年十月，《细胞》上刊登了一项名为NT001的多中心1b期临床研究，共纳入多线治疗失败的晚期黑色素瘤、非小细胞肺癌及膀胱癌<span style="color: black;">病人</span>，接受NEO-PV-01联合PD1单抗O药（nivolumab，Opdivo）治疗，<span style="color: black;">实验</span>结果<span style="color: black;">已然</span>出来了。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">①<span style="color: black;">截止</span>2019年4月共纳入34例<strong style="color: blue;">黑色素瘤<span style="color: black;">病人</span></strong>，结果<span style="color: black;">表示</span>NEO-PV-01联合O药的<span style="color: black;">ORR为47%</span>，中位PFS未达到，12个月的PFS率为56%，<span style="color: black;">寓意</span>着<span style="color: black;">PFS<span style="color: black;">已然</span>超过了1年</span>。与O药、K药单药的<span style="color: black;">实验</span>进行间接对比，O/K后线的PFS为3.1-6.9个月，相比之下<span style="color: black;">联合<span style="color: black;">方法</span>PFS成功延长了一倍及以上</span>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/oZVJebibh9RmLqYBt9InvOwP0iaXKG7ick0d4xqZVE7oLP70Crv79zF6VpNQlHxe6IAI3JNmMVArD8Kzf0bUo8CnQ/640?wx_fmt=png&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">②在吸烟<span style="color: black;">关联</span>的<strong style="color: blue;">非小细胞肺癌<span style="color: black;">病人</span></strong>中，27例<span style="color: black;">病人</span><span style="color: black;">运用</span>联合治疗的<span style="color: black;">ORR为22%，中位PFS为5.6个月</span>。与K/O药单药的<span style="color: black;">实验</span>间接对比，PFS<span style="color: black;">亦</span>有所<span style="color: black;">加强</span>（PD1单药的PFS为2.3-4.2个月）。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/oZVJebibh9RmLqYBt9InvOwP0iaXKG7ick0c5H9Af0gicFKgzjvGtYGufDnCMiccS4NbicRNrIFAjEysXx9bjk2MB6gw/640?wx_fmt=png&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">③在21例<strong style="color: blue;">膀胱癌</strong>的<span style="color: black;">病人</span>中，疫苗+O药的<span style="color: black;">ORR为24%，中位PFS为5.6个月</span>。与O药、K药、T药（PDL1单抗）间接比较，<span style="color: black;">联合组的PFS延长了一倍及以上</span>（T/K/O的PFS为2.7、2.8、2.1个月）。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/oZVJebibh9RmLqYBt9InvOwP0iaXKG7ick0Ukiapc2lgH1gvD3ibgMbtzMF06OEibk3Z2eJXY5FDqcsAh7DZibicrCrTicQ/640?wx_fmt=png&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">04</strong></p><img src="https://mmbiz.qpic.cn/mmbiz_svg/oLU121BePGns866fNeNCBA0E8n3Yic0oUCickfdZ9ZvdarMe37IJ1bsJ3nHO6fA1R9M3JNHXajhyarEJu3WYxib0PP9OSPeibRdR/640?wx_fmt=svg&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;">
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">DCVAC/LuCa疫苗进军晚期非小细胞肺癌一线治疗，总缓解率大幅<span style="color: black;">提高</span>！</strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">DCVAC/LuCa<span style="color: black;">是由于</span>SOTIO<span style="color: black;">开发</span>的针对非小细胞肺癌<span style="color: black;">病人</span>的树突状细胞疫苗。<span style="color: black;">经过</span>将树突状细胞与裂解死亡后的<span style="color: black;">病人</span>自体肺癌细胞所释放的抗原物质融合，使树突状细胞<span style="color: black;">得到</span>识别肺癌细胞的能力，并经过体外扩增后回输入<span style="color: black;">病人</span><span style="color: black;">身体</span>进行治疗。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">在一项冲击一线治疗<span style="color: black;">方法</span>的<span style="color: black;">科研</span>中，<span style="color: black;">科研</span>者<span style="color: black;">选择</span>了来自12个<span style="color: black;">科研</span>中心的112例<span style="color: black;">病人</span>。接受DCVAC/LuCa联合化疗治疗的<span style="color: black;">病人</span><span style="color: black;">mOS为15.5个月，mPFS为6.74个月，ORR45%</span>；仅接受化疗的<span style="color: black;">病人</span>为mOS为11.8个月，mPFS为5.63个月，ORR34%。虽然PFS相差<span style="color: black;">没</span>几，<strong style="color: blue;"><span style="color: black;">然则</span>OS延长了7个月</strong>，将IV期非小细胞肺癌<span style="color: black;">病人</span>的<span style="color: black;">死亡<span style="color: black;">危害</span>降低了足有46%</span>！</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/oZVJebibh9RmLqYBt9InvOwP0iaXKG7ick0fVl53C2BdC0V3llnraD70G6HvT0Dxu8VQBy88ztBQMfdBopUiaWwzVA/640?wx_fmt=png&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"></p><img src="https://mmbiz.qpic.cn/mmbiz_svg/oLU121BePGns866fNeNCBA0E8n3Yic0oUCickfdZ9ZvdarMe37IJ1bsJ3nHO6fA1R9M3JNHXajhyarEJu3WYxib0PP9OSPeibRdR/640?wx_fmt=svg&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;">
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">乳腺癌</strong></p><img src="https://mmbiz.qpic.cn/mmbiz_svg/oLU121BePGns866fNeNCBA0E8n3Yic0oUCy1cqCFLLgv9PicxTG86bSyIaOHib4oHsDnE6Jic2bfvHfxQ24ibUMnMibZBtShDdftcF/640?wx_fmt=svg&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;">
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">01</strong></p><img src="https://mmbiz.qpic.cn/mmbiz_svg/oLU121BePGns866fNeNCBA0E8n3Yic0oUCickfdZ9ZvdarMe37IJ1bsJ3nHO6fA1R9M3JNHXajhyarEJu3WYxib0PP9OSPeibRdR/640?wx_fmt=svg&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;">
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">GP2实现癌症<span style="color: black;">病人</span>5年<span style="color: black;">没</span>一例复发，乳腺癌迎来治愈新曙光！</strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">11月9日，Greenwich LifeSciences<span style="color: black;">颁布</span>了旗下乳腺癌疗法 IIb 期临床<span style="color: black;">实验</span>结果，46例接受GP2+GM-CSF治疗的HER2+<span style="color: black;">病人</span>的<span style="color: black;">5年DFS<span style="color: black;">出现</span>率为100%，<span style="color: black;">没</span>一复发！</span>而接受GM-CSF治疗的50例安慰剂<span style="color: black;">病人</span>的5年DFS<span style="color: black;">出现</span>率为<span style="color: black;">89.4%（95%CI:76.2，95.5%）（p=0.0338）</span>。为乳腺癌治愈带来新曙光！</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/oZVJebibh9RmLqYBt9InvOwP0iaXKG7ick0taYxlpdOtWwd44XczicEzsCpNoNC0EbzzU8qDfLiaKG7U2nn9NTye0HQ/640?wx_fmt=png&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">02</strong></p><img src="https://mmbiz.qpic.cn/mmbiz_svg/oLU121BePGns866fNeNCBA0E8n3Yic0oUCickfdZ9ZvdarMe37IJ1bsJ3nHO6fA1R9M3JNHXajhyarEJu3WYxib0PP9OSPeibRdR/640?wx_fmt=svg&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;">
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">挑战三阴！FDA授予NeuVax疫苗快速通道资格！</strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">NeuVax（nelipepimut-S，NPS，前<span style="color: black;">叫作</span>E75）是美国<span style="color: black;">开发</span>的乳腺癌HER-2蛋白疫苗。NeuVax与免疫佐剂粒细胞-巨噬细胞集落刺激因子（GM-CSF）联合应用时，被证实能够<span style="color: black;">导致</span>强大的抗HER2免疫应答。先前<span style="color: black;">科研</span>已证实NeuVax可改善HER-2阳性乳腺癌<span style="color: black;">病人</span>的总<span style="color: black;">存活</span>率，且耐受性良好，不良反应轻微。<strong style="color: blue;">FDA授予NeuVax用于接受标准护理治疗的HER2表达为低至中等水平（HER2 1+或2+）<span style="color: black;">初期</span>乳腺癌（<span style="color: black;">包含</span>三阴性乳腺癌）<span style="color: black;">病人</span>的快速通道资格。</strong><span style="color: black;">日前</span>，NeuVax计划开展III期<span style="color: black;">科研</span>，<span style="color: black;">评定</span>NeuVax疫苗联合曲妥珠单抗、GM-CSF单药疗法<span style="color: black;">做为</span>维持疗法，用于TNBC<span style="color: black;">病人</span>在接受标准护理治疗后进行辅助治疗。</p><img src="https://mmbiz.qpic.cn/mmbiz_svg/oLU121BePGns866fNeNCBA0E8n3Yic0oUCickfdZ9ZvdarMe37IJ1bsJ3nHO6fA1R9M3JNHXajhyarEJu3WYxib0PP9OSPeibRdR/640?wx_fmt=svg&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;">
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">宫颈癌</strong></p><img src="https://mmbiz.qpic.cn/mmbiz_svg/oLU121BePGns866fNeNCBA0E8n3Yic0oUCy1cqCFLLgv9PicxTG86bSyIaOHib4oHsDnE6Jic2bfvHfxQ24ibUMnMibZBtShDdftcF/640?wx_fmt=svg&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;">
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">01</strong></p><img src="https://mmbiz.qpic.cn/mmbiz_svg/oLU121BePGns866fNeNCBA0E8n3Yic0oUCickfdZ9ZvdarMe37IJ1bsJ3nHO6fA1R9M3JNHXajhyarEJu3WYxib0PP9OSPeibRdR/640?wx_fmt=svg&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;">
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">疫苗BVAC-C在晚期宫颈癌中<span style="color: black;">表示</span>出新<span style="color: black;">期盼</span></strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2020 AACR虚拟年会的<span style="color: black;">科研</span>结果<span style="color: black;">表示</span>，该<span style="color: black;">实验</span>总共有11名<span style="color: black;">身患</span>多发转移性或复发性HPV 16或HPV 18阳性子宫颈癌的<span style="color: black;">病人</span>参与<span style="color: black;">实验</span>，所有<span style="color: black;">病人</span>入选该<span style="color: black;">实验</span>前均已接受<span style="color: black;">最少</span>1种铂类化学疗法联合治疗。在9例可<span style="color: black;">评定</span>的<span style="color: black;">病人</span>中，有5例<span style="color: black;">疾患</span>稳定，<span style="color: black;">DCR为56％，mPFS为6.8个月</span>。6个月时的mOS为89％，12个月时mOS率为65％。这<span style="color: black;">寓意</span>着BVAC-C可能将为晚期宫颈癌<span style="color: black;">病人</span>带来新的<span style="color: black;">期盼</span>。</p><img src="https://mmbiz.qpic.cn/mmbiz_svg/oLU121BePGns866fNeNCBA0E8n3Yic0oUCickfdZ9ZvdarMe37IJ1bsJ3nHO6fA1R9M3JNHXajhyarEJu3WYxib0PP9OSPeibRdR/640?wx_fmt=svg&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;">
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">卵巢癌</strong></p><img src="https://mmbiz.qpic.cn/mmbiz_svg/oLU121BePGns866fNeNCBA0E8n3Yic0oUCy1cqCFLLgv9PicxTG86bSyIaOHib4oHsDnE6Jic2bfvHfxQ24ibUMnMibZBtShDdftcF/640?wx_fmt=svg&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;">
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">01</strong></p><img src="https://mmbiz.qpic.cn/mmbiz_svg/oLU121BePGns866fNeNCBA0E8n3Yic0oUCickfdZ9ZvdarMe37IJ1bsJ3nHO6fA1R9M3JNHXajhyarEJu3WYxib0PP9OSPeibRdR/640?wx_fmt=svg&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;">
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">两年<span style="color: black;">存活</span>率100%！OCDC疫苗前景<span style="color: black;">没</span>限</strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">该<span style="color: black;">科研</span>尝试采用氧化自体全肿瘤细胞裂解物（OCDC）形成的自体树突状细胞进行免疫治疗。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/oZVJebibh9RmLqYBt9InvOwP0iaXKG7ick0njbTOJPPFkCvyR9h3pEhw33AyGf26W6vbyDJMKibMND2DhW4b2Nk3gw/640?wx_fmt=png&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">科研</span>人员将晚期卵巢癌<span style="color: black;">病人</span>外周血培育出的树突状细胞暴露在<span style="color: black;">病人</span>的肿瘤提取物中，并用干扰素γ激活细胞。最后将这些<span style="color: black;">持有</span>肿瘤细胞“碎片”或标识的树突状细胞重新注射会<span style="color: black;">病人</span><span style="color: black;">身体</span>，激活并<span style="color: black;">加强</span><span style="color: black;">病人</span><span style="color: black;">身体</span>的T细胞，<span style="color: black;">导致</span>对肿瘤细胞的免疫反应。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">在<span style="color: black;">哪些</span>对其重输回<span style="color: black;">身体</span>的树突状细胞有所应答的<span style="color: black;">病人</span>中，<strong style="color: blue;">晚期卵巢癌<span style="color: black;">病人</span>的2年总<span style="color: black;">存活</span>率达到了100%！</strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">02</strong></p><img src="https://mmbiz.qpic.cn/mmbiz_svg/oLU121BePGns866fNeNCBA0E8n3Yic0oUCickfdZ9ZvdarMe37IJ1bsJ3nHO6fA1R9M3JNHXajhyarEJu3WYxib0PP9OSPeibRdR/640?wx_fmt=svg&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;">
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">DCVAC/OvCa延长复发性卵巢癌<span style="color: black;">病人</span><span style="color: black;">存活</span>期超过一年！</strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">DCVAC是一种基于树突状细胞制造的疫苗，由SOTIO研发，<span style="color: black;">经过</span>将树突状细胞与裂解死亡后的<span style="color: black;">病人</span>自体肺癌细胞所释放的抗原物质融合，使树突状细胞<span style="color: black;">得到</span>识别肺癌细胞的能力，并经过体外扩增后回输入<span style="color: black;">病人</span><span style="color: black;">身体</span>进行治疗。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/oZVJebibh9RmLqYBt9InvOwP0iaXKG7ick0ghBAsiaaDqA8S65e1l852FHVPmNOD9EIkwqic0DOsUeWgLubq09usKPA/640?wx_fmt=png&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">近期，一款由SOTIO<span style="color: black;">开发</span>的、名为DCVAC/OvCa的树突状细胞疫苗在卵巢癌治疗<span style="color: black;">行业</span>取得了突破性的<span style="color: black;">发展</span>。DCVAC/OvCa二线治疗卵巢癌<span style="color: black;">死亡<span style="color: black;">危害</span>降低62%，总<span style="color: black;">存活</span>期<span style="color: black;">明显</span><span style="color: black;">增多</span>13.4个月，中位<span style="color: black;">没</span><span style="color: black;">发展</span><span style="color: black;">存活</span>期<span style="color: black;">增多</span>1.2个月！</span>联合树突状细胞疫苗治疗的<span style="color: black;">病人</span>，总<span style="color: black;">存活</span>期延长超过一年、<span style="color: black;">存活</span>期接近仅接受化疗<span style="color: black;">病人</span>的两倍！</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/oZVJebibh9RmLqYBt9InvOwP0iaXKG7ick07rA3sIp1oQb7CbmyyhaUgicSjcsSqKQmoWLI3rwPibDhd8wRbgQtyFlQ/640?wx_fmt=png&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">日前</span>，<span style="color: black;">全世界</span>在研的肿瘤疫苗临床<span style="color: black;">实验</span>有200多项，以上介绍的只是冰山一角。<span style="color: black;">科研</span>者们<span style="color: black;">暗示</span><span style="color: black;">倘若</span>成功，个体化疫苗将被用于各个癌种，<span style="color: black;">拥有</span>巨大<span style="color: black;">潜能</span>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">参考资料：</strong></p><img src="https://mmbiz.qpic.cn/mmbiz_svg/oLU121BePGns866fNeNCBA0E8n3Yic0oU54ruGJSledDVj76ib5hLOj2CtDRzKFypZwkBCTyXhhQiae3JByBvVuHgmJ9WAHX3Ey/640?wx_fmt=svg&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;">
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">https://ose-immuno.com/wp-content/uploads/2020/04/EN_200401_IDMC-Atalante_VF.pdf</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">https://www.cell.com/cell/fulltext/S0092-8674(20)31141-7?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867420311417%3Fshowall%3Dtrue#figs2</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">https://www.onclive.com/view/vaccine-bvacc-shows-early-promise-in-cervical-cancer</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">声明：本资料中<span style="color: black;">触及</span>的信息仅供参考，请遵从<span style="color: black;">大夫</span>或其他医疗卫生专业人士的意见或<span style="color: black;">指点</span>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">本文版权归找药宝典所有，任何个人或<span style="color: black;">公司</span>转载需<span style="color: black;">得到</span>找药宝典授权，在授权范围内<span style="color: black;">运用</span>，并标注<span style="color: black;">源自</span>“找药宝典”。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">媒介</span>合作请联系：xiaoxi730893</p><img src="https://mmbiz.qpic.cn/mmbiz_png/oZVJebibh9RmLqYBt9InvOwP0iaXKG7ick0mmdwxAAZtfajquETGqd5VWT6ibtDbODNYDkKsUemiccxEgJdbS2FBAhQ/640?wx_fmt=png&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;">
外链论坛的成功举办，是与各位领导、同仁们的关怀和支持分不开的。在此，我谨代表公司向关心和支持论坛的各界人士表示最衷心的感谢！ 外贸网站建设方法 http://www.fok120.com/ 论坛的成果是显著的，但我们不能因为成绩而沾沾自喜。 我完全同意你的看法，期待我们能深入探讨这个问题。
页:
[1]